FindTrial
Sign In

Clinical study on improving the success rate of hepatitis B vaccination after liver transplantation for hepatitis B related diseases

Clinical study on improving the success rate of hepatitis B vaccination after liver transplantation for hepatitis B related diseases

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054071
Enrollment
Unknown
Registered
2021-12-08
Start date
2022-01-01
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B related diseases after liver transplantation

Interventions

control group:Injection of recombinant hepatitis B vaccine 20ug (Shenzhen Kangtai Co., Ltd.)
Experimental group :Injection of recombinant hepatitis B vaccine 60ug (Shenzhen Kangtai Co., Ltd.)

Sponsors

Beijing You'an Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. The time after liver transplantation is more than 18 months; 3. Postoperative use of nucleoside analogs combined with hepatitis B immune globulin prophylaxis; 4. No recurrence of primary disease; 5. Normal liver and kidney function; 6. Serum HBV DNA and hepatitis B surface antigen test were negative.

Exclusion criteria

Exclusion criteria: Allergic to hepatitis B vaccine.

Design outcomes

Primary

MeasureTime frame
Hepatitis B surface antibody titer;—

Secondary

MeasureTime frame
Liver function;HBV-DNA;Hepatitis B surface antigen;Analysis of T cell function;—

Countries

China

Contacts

Public ContactLi Guangming

Beijing You'an Hospital Affiliated to Capital Medical University

liguangming@ccmu.edu.cn+86 13501122244

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026